



Hematology 2023

AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM

65th ASH® Annual Meeting and Exposition

Editors

Hanny Al-Samkari, MD

Executive Editor, *Hematology 2023*
Massachusetts General Hospital
Boston, Massachusetts

Alison R. Walker, MD, MPH, MBA

Deputy Editor, *Hematology 2023*
H. Lee Moffitt Cancer Center
Tampa, Florida

Rakhi P. Naik, MD, MHS

Deputy Editor, *Hematology 2023*
Johns Hopkins Medicine
Baltimore, Maryland

Alex F. Herrera, MD

Deputy Editor, *Hematology 2023*
City of Hope
Duarte, California

Ang Li, MD, MS

Special Section Editor, *Hematology 2023*
Baylor College of Medicine
Houston, Texas

© 2023 by The American Society of Hematology
ISSN 1520-4391 (print), 1520-4383 (online)

Hematology, the ASH Education Program, is published annually by The American Society of Hematology (ASH) in one volume per year.

All business correspondence and purchase and reprint requests should be addressed to The American Society of Hematology, 2021 L Street, NW, Suite 900, Washington, DC 20036, USA; phone: 202-776-0544; fax: 202-776-0545; e-mail: ASH@hematology.org.

Hematology, the ASH Education Program, is available on the Internet at <https://ashpublications.org/hematology>.

© 2023 by The American Society of Hematology. All rights reserved. Copyright is not claimed in any works of the United States Government. Except as expressly permitted in this statement, no part of this publication may be used (as here in after defined) in any form or by any means now or hereafter known, electronic or mechanical, without permission in writing from the Publisher, The American Society of Hematology. For purposes of this notice, the term "use" includes but is not limited to reproduction, photocopying, storage in a retrieval system, translation, and transmittal. The Publisher hereby consents to the use of this publication or any part hereof for any noncommercial educational purpose within the health field such as classroom instruction and clinical and residency training. This publication or any part thereof may be used for educational purposes at conferences, continuing education courses, and other educational activity, provided no fee or other compensation is charged therefor. All materials so used must acknowledge the Publisher's copyright therein as "© 2023 by The American Society of Hematology." When requesting the Publisher's permission to use this publication or any part thereof, please contact the Copyright Clearance Center at 222 Rosewood Drive, Danvers, MA 01923, USA; phone: 978-750-8400; fax: 978-750-4470; or The American Society of Hematology Publications Department at 2021 L Street, NW, Suite 900, Washington, DC 20036, USA; phone: 202-776-0544; fax: 202-776-0545.

Article Citations

Cite articles in this volume by listing Author(s), Title, *Hematology Am Soc Hematol Educ Program*. 2023;2023: beginning page number-ending page number.

Hematology Rights and Permission

To request permission to reprint or reuse *Hematology* articles, figures, or tables, please visit the *Hematology* page at the Copyright Clearance Center (<https://marketplace.copyright.com/rs-ui-web/mp/details/journal/123161909>).

The Publisher disclaims responsibility for opinions expressed by the authors.

Committee on Educational Affairs

Jennifer R. Brown, MD, PhD ('25) (Chair)
Anjali Advani, MD ('23) (Vice Chair)
Juan Pablo Alderuccio, MD ('26)
Marc J. Braunstein, MD, PhD ('25)
Nicholas R. Burwick, MD ('25)
Shruti Chaturvedi, MBBS, MS ('25)
Faith Davies, MD ('24)
Amy E. DeZern, MD, MHS ('23)
Nobuko Hijiya, MD ('24)
Margaret Kasner, MD ('26)
Kah Poh (Melissa) Loh, MD ('27)
Martha P. Mims, MD, PhD ('27)
Casey L. O'Connell, MD ('23)
Heather A. O'Leary, PhD ('23)
Nicki Panoskaltzis, MD, PhD ('25)

Ex Officio Members

Robert A. Brodsky, MD ('23) – President
Mohandas Narla, DSc ('24) – President-Elect
Belinda Avalos, MD ('25) – Vice President

Liaisons

Hanny Al-Samkari, MD ('24) – Executive Editor, *Hematology ASH Education Program*
Jean M. Connors, MD ('23) – 2023 Education Program Co-Chair
Laura M. De Castro, MD ('23) – Member, Committee on Practice
Amy E. DeZern, MD, MHS ('23) – 2023 Education Program Co-Chair
Cynthia E. Dunbar, MD ('24) – Secretary
Brady L. Stein, MD ('25) – Senior Executive Editor, ASH-SAP 9

Cover: Illustration of activated platelets.
Source: Kateryna Kon/Science Photo Library.

This activity is supported by educational grants from AstraZeneca; Incyte Corp.; Jazz Pharmaceuticals, Inc.; Merck Sharp & Dohme Corp.; and Novartis Pharmaceuticals Corp.

Contents

- x Editors' Message
- xi Reviewers
- xii Continuing Medical Education Information

Ham-Wasserman Lecture

- 1 Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond**
ANDREAS GREINACHER AND THEODORE E. WARKENTIN

Acquired Hemophilia A Diagnosis and Management

- 11 Diagnosis and laboratory monitoring of hemophilia A**
SEAN PLATTON, SUTHESH SIVAPALARATNAM, AND PRIYANKA RAHEJA
- 19 Immunotherapy of acquired hemophilia A**
ANDREAS TIEDE
- 24 The role of emicizumab in acquired hemophilia A**
JACQUELINE POSTON AND REBECCA KRUSE-JARRES

Alphabet Soup: Challenging Consults on the Pediatric Units

- 31 Inflamed—HLH, MAS, or something else?**
ASHISH KUMAR, EILY COURNOYER, AND LEONARD NAYMAGON
- 37 Too many white cells—TAM, JMML, or something else?**
ALEXANDRA SATTY, ELLIOT STIEGLITZ, AND NICOLE KUCINE
- 43 Where have all the platelets gone? HIT, DIC, or something else?**
ROHITH JESUDAS AND CLIFFORD M. TAKEMOTO

Are We Personalizing MDS Therapy in 2023?

- 51 How to classify risk based on clinical and molecular modeling: integrating molecular markers in the risk assessment of myelodysplastic syndrome**
RENA R. XIAN
- 59 Next-generation therapy for lower-risk MDS**
MARIE SÉBERT
- 65 Frontline treatment options for higher-risk MDS: can we move past azacitidine?**
DAVID A. SALLMAN AND ZHUOER XIE
- 73 EVIDENCE-BASED MINIREVIEW**
Mutational screening to improve the transplantation decision-making process in MDS
ALESSIA CAMPAGNA AND MATTEO G. DELLA PORTA

CAR T Cells in ALL: Bridge or Definitive Therapy?

- 77 Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL**
REBECCA EPPERLY AND NIRALI N. SHAH
- 84 Stem cell transplantation for ALL: you've always got a donor, why not always use it?**
DAVID SHYR, KARA L. DAVIS, AND ALICE BERTAINA
- 91 Preventing relapse after CD19 CAR T-cell therapy for pediatric ALL: the role of transplant and enhanced CAR T cells**
AIMEE C. TALLEUR, SWATI NAIK, AND STEPHEN GOTTSCHALK

Energizing the Red Cell: Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias

- 97 Pyruvate kinase activators for treatment of pyruvate kinase deficiency**
RACHAEL F. GRACE
- 107 Pyruvate kinase activators: targeting red cell metabolism in sickle cell disease**
JULIA Z. XU AND GREGORY M. VERCELLOTTI
- 114 Pyruvate kinase activators: targeting red cell metabolism in thalassemia**
KEVIN H.M. KUO
- 121 EVIDENCE-BASED MINIREVIEW**
When should gene therapy be considered for transfusion-dependent β -thalassemia patients?
CHERYL MENSAH AND SUJIT SHETH

Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes: Too Early, Too Late, Just Right?

- 125 Clonal evolution in inherited marrow failure syndromes predicts disease progression**
KRISTEN E. SCHRATZ
- 135 Minimal intensity conditioning strategies for bone marrow failure: is it time for "preventative" transplants?**
SUNEET AGARWAL
- 141 Posttransplant complications in patients with marrow failure syndromes: are we improving long-term outcomes?**
ZAHRA HUDDA AND KASIANI C. MYERS

Graft-Versus-Host Disease: Is an Ounce of Prevention Worth a Pound of Cure?

- 149 Planning GvHD preemptive therapy: risk factors, biomarkers, and prognostic scores**
JACOB ROZMUS, JOHN E. LEVINE, AND KIRK R. SCHULTZ
- 155 Novel approaches to acute graft-versus-host disease prevention**
BENJAMIN WATKINS AND MUNA QAYED
- 164 Chronic GVHD: review advances in prevention, novel endpoints, and targeted strategies**
IDOROENYI AMANAM, SALMAN OTOUKESH, MONZR M. AL MALKI, AND AMANDEEP SALHOTRA
- 171 EVIDENCE-BASED MINIREVIEW**
Should posttransplant cyclophosphamide be considered standard of care for pediatric transplantation of acute leukemia?
ERIN E. DOHERTY AND ROBERT A. KRANCE

Have We Optimized Therapy Yet for Patients with AML?

- 175 Improving long-term outcomes with intensive induction chemotherapy for patients with AML**
CHRISTOPH RÖLLIG
- 186 The approach of HMA plus VEN with or without BMT for all patients with AML**
HEATHER J. MALE AND TARA L. LIN

- 192 The future paradigm of HMA + VEN or targeted inhibitor approaches: sequencing or triplet combinations in AML therapy**

SANGEETHA VENUGOPAL AND JUSTIN WATTS

Hematologic Toxicity of Immunotherapies

- 198 Recognizing, defining, and managing CAR-T hematologic toxicities**

KAI REJESKI, MARION SUBKLEWE, AND FREDERICK L. LOCKE

- 209 Checkpoint inhibitors**

MICHAEL H. KROLL

- 216 Bispecific antibody therapies**

LUIZ HENRIQUE DE ASSIS, DANIEL EL FASSI, AND MARTIN HUTCHINGS

Hematologists and the Care of Pregnant Women

- 223 Identifying and treating iron deficiency anemia in pregnancy**

ADAM K. LEWKOWITZ AND METHODIUS G. TUULI

- 229 Management of pregnant women who have bleeding disorders**

ANDRA H. JAMES, LUIS D. PACHECO, AND BARBARA A. KONKLE

- 237 Prevention, diagnosis, and management of PE and DVT in pregnant women**

BARRY KEVANE AND FIONNUALA NÍ ÁINLE

Hematologists as Lifesavers: Inpatient Hematology Emergencies

- 248 How to avoid early mortality in acute promyelocytic leukemia**

OLUWATOBI ODETOLA AND MARTIN S. TALLMAN

- 254 How to manage ITP with life-threatening bleeding**

JEAN M. CONNORS AND STEVEN FEIN

- 259 Inpatient recognition and management of HLH**

ADI ZOREF-LORENZ, MARTIN ELLIS, AND MICHAEL B. JORDAN

Hemostasis in Patients with Severe Liver Disease

- 267 How to assess hemostasis in patients with severe liver disease**

TON LISMAN

- 274 How to manage hemostasis in patients with liver disease during interventions**

LARA N. ROBERTS

- 281 How to manage splanchnic vein thrombosis in patients with liver disease**

NICOLETTA RIVA AND WALTER AGENO

- 289 EVIDENCE-BASED MINIREVIEW**

Direct oral anticoagulants to treat deep venous thrombosis and pulmonary embolism in patients with cirrhosis: are we there yet?

AMBER AFZAL AND JORDAN SCHAEFER

Hot Topics in Blood Donation: Donor Risks and Social Justice

- 294 MSM and blood donation: shifting to individualized risk assessment**

MINDY GOLDMAN

- 299 Clonal hematopoiesis in frequent whole blood donors**

DARJA KARPOVA

- 305 T-cell lymphopenia in frequent volunteer platelet donors**

RICHARD M. KAUFMAN

How Can We Manage High-Risk Hematologic Malignancies in the Community?

- 311 Acute leukemias and complicated lymphomas: pearls to optimize management when patients stay local**

DIPTI PATEL-DONNELLY AND MITUL GANDHI

318 Multiple myeloma: a paradigm for blending community and academic care

JESÚS G. BERDEJA

324 Clinical research in the community

RUEMU EJEDAFETA BIRHIRAY AND MAYA NICOLE BIRHIRAY

How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T Cells and Bispecific Antibodies

332 Current use of bispecific antibodies to treat multiple myeloma

HOLLY LEE, PAOLA NERI, AND NIZAR J. BAHLIS

340 Current use of CAR T cells to treat multiple myeloma

ROSS S. FIRESTONE AND SHAM MAILANKODY

348 Managing side effects: guidance for use of immunotherapies in multiple myeloma

EMILY C. LIANG AND SURBHI SIDANA

How Do We Calibrate Cellular Therapy for Lymphoma in 2023?

357 CAR T-cell therapy in aggressive lymphomas—identifying prognostic and predictive markers

ALBERTO MUSSETTI, NICOLE FABBRI, AND ANNA SUREDA

364 Management of aggressive lymphoma after CAR T-cell therapy failure

LORETTA J. NASTOUPIL AND SWETHA KAMBHAMPATI

370 Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas

AJAY MAJOR AND MANALI KAMDAR

382 EVIDENCE-BASED MINIREVIEW

Barriers to accessing cellular therapy for patients receiving care in community practices

CHIJOKE NZE AND CHRISTOPHER R. FLOWERS

How Do We Enhance Results in Rare Hematologic Malignancies?

386 Langerhans cell histiocytosis: promises and caveats of targeted therapies in high-risk and CNS disease

OUSSAMA ABLA

396 Mastocytosis demystified

SCOTT VEITCH AND DEEPTI H. RADIA

407 Amyloid consults do not have to be vexing

ANITA D'SOUZA

How Do We Extend Survival for Patients with CLL in 2023?

413 MRD-directed therapy in CLL: ready for prime time?

JOANNA M. RHODES, CARLOS A. LOPEZ, AND JACQUELINE C. BARRIENTOS

421 Dual-targeted regimens for the frontline treatment of CLL

CHAITRA UJJANI

427 Richter transformation—is there light at the end of this tunnel?

TOBY A. EYRE

How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?

433 A rational approach to functional high-risk myeloma

FRANCESCA GAY, GIUSEPPE BERTUGLIA, AND ROBERTO MINA

443 Considerations for next therapy after anti-CD38 monoclonal antibodies used as first line

MONIQUE HARTLEY-BROWN AND ATEH ZINKENG

450 Options at the time of relapse after anti-BCMA therapy

BEATRICE RAZZO, ALFRED L. GARFALL, AND ADAM D. COHEN

How Do We Tackle Remaining Clinical Challenges in CML?

- 459 Accelerated-phase CML: de novo and transformed**
NARANIE SHANMUGANATHAN AND TIMOTHY P. HUGHES
- 469 Resistance mutations in CML and how we approach them**
SIMONA SOVERINI
- 476 Atypical CML: diagnosis and treatment**
MASSIMO BRECCIA

How Is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?

- 483 Hodgkin lymphoma treatment for older persons in the modern era**
ANDREW M. EVENS, MARSHALL McKENNA, YUN KYOUNG RYU TIGER, AND JENICA N. UPSHAW
- 500 Management of limited-stage Hodgkin lymphoma**
TAHA AL-JUHAISHI AND SAIRAH AHMED
- 510 The optimal management of relapsed and refractory Hodgkin lymphoma: post-brentuximab and checkpoint inhibitor failure**
NATALIE S. GROVER, CHRISTOPHER DITTUS, ASTHA THAKKAR, AND ANNE W. BEAVEN

Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle?

- 519 Using disease-modifying therapies in sickle cell disease**
PARUL RAI AND KENNETH I. ATAGA
- 532 The range of haploidentical transplant protocols in sickle cell disease: all haplos are not created equally**
ADETOLA A. KASSIM AND MICHAEL R. DEBAUN
- 542 Gene therapy for sickle cell disease**
ALEXIS LEONARD AND JOHN F. TISDALE

Inherited Bone Marrow Failure Syndromes: from Pediatrics to Adult

- 548 When to consider inherited marrow failure syndromes in adults**
FERNANDA GUTIERREZ-RODRIGUES, BHAVISHA A. PATEL, AND EMMA M. GROARKE
- 556 Management of Fanconi anemia beyond childhood**
TIMOTHY S. OLSON
- 563 Clinical manifestations of telomere biology disorders in adults**
MARENA R. NIEWISCH, FABIAN BEIER, AND SHARON A. SAVAGE

Not Kids Anymore and Not Adults Yet: How Do We Treat Adolescent and Young Adult (AYA) Patients with ALL?

- 573 Leveraging health care technology to improve health outcomes and reduce outcome disparities in AYA leukemia**
JOHN C. MOLINA AND SETH ROTZ
- 581 Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment**
SANYUKTA K. JANARDAN AND TAMARA P. MILLER
- 587 Acute lymphoblastic leukemia in young adults: which treatment?**
ANNABELLE ANANDAPPA AND EMILY CURRAN

Ongoing Challenges in the Management of VTE

- 593 The dos, don'ts, and nuances of thrombophilia testing**
THITA CHIASAKUL AND KENNETH A. BAUER
- 600 Provoked vs minimally provoked vs unprovoked VTE: does it matter?**
CECILIA BECATTINI AND LUDOVICA ANNA CIMINI

606 How to diagnose and manage antiphospholipid syndrome

ANNE HUBBEN AND KEITH R. McCRAE

614 EVIDENCE-BASED MINIREVIEW

Should older patients with low weight and CKD receive full-dose DOACs for treatment of acute proximal DVT?

NICOLAS GALLASTEGUI AND CAMILA MASIAS

The Iron Revolution!

617 Sex, lies, and iron deficiency: a call to change ferritin reference ranges

KYLEE MARTENS AND THOMAS G. DeLOUGHERY

622 IV iron formulations and use in adults

LAYLA VAN DOREN AND MICHAEL AUERBACH

630 Intravenous iron therapy in pediatrics: who should get it and when is the right time?

CLAY T. COHEN AND JACQUELYN M. POWERS

636 EVIDENCE-BASED MINIREVIEW

Incidence, mechanism, and consequences of IV iron-induced hypophosphatemia

KYLEE L. MARTENS AND MYLES WOLF

Transfusion Support in Sickle Cell Disease

640 Managing pregnancy in patients with sickle cell disease from a transfusion perspective

ANOOSHA HABIBI, ALEXANDRA BENACHI, AND EDOUARD LECARPENTIER

646 Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease

SHANNON KELLY

653 Alloimmunization and hyperhemolysis in sickle cell disease

FRANCE PIRENNE AND CORINNE PONDARRÉ

What Are the Advances in Myeloproliferative Neoplasms Affecting Management?

660 Cytoreduction for ET and PV: who, what, when, and how?

DOUGLAS TREMBLAY

667 Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations

HARINDER GILL, GARRET M. K. LEUNG, AND YOK-LAM KWONG

676 Are transplant indications changing for myelofibrosis?

JEANNE PALMER

What Are Treatment Options for Patients with Relapsed, Refractory, or Persistent AML?

682 Understanding differential technologies for detection of MRD and how to incorporate into clinical practice

JACQUELINE CLOOS, LOK LAM NGAI, AND MICHAEL HEUSER

691 Novel immunotherapies in the treatment of AML: is there hope?

MARION SUBKLEWE, VEIT BÜCKLEIN, DAVID SALLMAN, AND NAVAL DAVER

702 Novel therapies upon failure of HMA plus venetoclax

ONYEE CHAN AND ALISON R. WALKER

What Makes a Good Transplant Recipient? Putting the Puzzle Pieces Together

709 How old is too old? Frailty and geriatric assessments of older patients undergoing allogeneic HCT

REENA V. JAYANI

715 The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation

RONI SHOUVAL AND JOSHUA A. FEIN

723 Approaches to optimize outcomes in transplant recipients

ASMITA MISHRA

731 EVIDENCE-BASED MINIREVIEW

What makes a pediatric or young adult patient an appropriate transplant candidate?

MONICA S. THAKAR AND MOHAMED L. SORROR

Why Am I Getting Paged at 2 AM? Microangiopathic Emergencies

737 Labor and delivery: DIC, HELLP, preeclampsia

JULIANA PEREZ BOTERO AND JENNIFER JURY McINTOSH

745 Medical consult: aHUS, TTP? How to distinguish and what to do

CHARLOTTE M. STORY, GLORIA F GERBER, AND SHRUTI CHATURVEDI

754 Consumptive coagulopathy in the ICU


ANDREW RETTER AND BEVERLEY J. HUNT

Editors' Message

Welcome to the 65th annual meeting of the American Society of Hematology. In addition to meeting friends and colleagues old and new, forging collaborations, and learning of the promising new advances in hematology, we hope you will discover that this year's meeting will not just meet but exceed the high standards for education for which the ASH Education Program is known. With a complete set of rigorously peer-reviewed, case-based, concise articles for this year's education program replete with useful figures and tables, our standards for *Hematology*, the ASH Education Program have never been higher, and we hope you will find that the quality of the content has never been better. We are also happy to say to all the bookworms out there that your pleas have been heard: the print version of *Hematology* is now once again available, this time for sale on an opt-in basis. This way, everyone wins: those who prefer to read the content online can continue to do so, and those who prefer a physical book can buy one if they wish. Best of all, no one needs to find room in their luggage for the tome, as preordered printed copies will be shipped soon after the meeting. In this volume, you will find articles for every session included in the education program, as well as a series of thought-provoking evidence-based minireviews, all written by international expert speaker-authors.

We must thank this year's education co-chairs, Dr. Jean Connors (classical hematology) and Dr. Amy DeZern (malignant hematology), for crafting a state-of-the-art education program on which this volume is based. Finally, *Hematology* is possible only thanks to the efforts of hundreds of invaluable peer reviewers and the diligent efforts of the ASH publications staff, including Ebony Stewart, Alison Beale, Jeremiah Murphy, Dax Rodulfa-Blemborg, Brian Cannon, Kenneth April, Keith Gigliello, Glenn Landis, and Nina Hoffman, among others. We are thankful for all of their work.

Enjoy, from your *Hematology* Editors!



Hanny Al-Samkari, MD




Alison R. Walker,
MD, MPH, MBA



Rakhi P. Naik, MD, MHS



Alex F. Herrera, MD



Ang Li, MD, MS

Reviewers

The editors thank the session chairs and the reviewers who worked hard to ensure the reliability of the material presented in *Hematology 2023*:

Jeremy S. Abramson
Catherine Aftandilian
Suneet Agarwal
Haris Ali
Pamela Blair Allen
Andrew S. Artz
Michael Auerbach
Nizar J. Bahlis
Brian J. Ball
Kenneth A. Bauer
Pavan K. Bendapudi
Alice Bertaina
Bhavana Bhatnagar
Neel S. Bhatt
Javier Bolaños-Meade
Prithviraj Bose
Robert A. Brodsky
Jennifer N. Brudno
Patricia A. R. Brunner
Andrew M. Brunner
John M. Burke
James B. Bussel
Scott Canna
Maria Domenica
Cappellini
Hetty E. Carraway
Marc Carrier
Shruti Chaturvedi
Luke Y. C. Chen
Yi-Bin Chen
Jacques Chiaroni
Satheesh Chonat
Douglas B. Cines
Nathan T. Connell
Mhairi Copland
Jorge Cortes
Luciano J. Costa
Alexey V. Danilov
Thomas G. DeLoughery
Amy E. DeZern
Anita D'Souza
Yvonne A. Efebera

Hesham Eissa
Andrew M. Evens
Lorenzo Falchi
Steven Fein
Courtney D. Fitzhugh
Radhika Gangaraju
David A. Garcia
Valentin Garcia-Gutierrez
Francesca Gay
Nilanjan Ghosh
Andreas Glenthøj
Ajay K. Gopal
Jed B. Gorlin
Rachael F. Grace
Tara Graff
Elizabeth A. Griffiths
Emma M. Groarke
Monique Hartley-Brown
David Henry
Gabriela Hobbs
Christopher S. Hourigan
Amanda Jacobson-Kelly
Nitin Jain
Siddhartha Jaiswal
Murali Janakiram
Martin F. Kaiser
Theodosia A. Kalfa
Manali Kamdar
Julie Kanter
Richard M. Kaufman
Sioban B. Keel
Steve Kitchen
Adam S. Kittai
Jan-Henning Klusmann
Paul Knoeb
Peter Kouides
Taxiarchis V. Kourelis
Nicolaus Kröger
Amrita Y. Krishnan
Rebecca Kruse-Jarres
Nicole Kucine
Stephan Ladisch

Michele P. Lambert
Rebecca Karp Leaf
Jerrold H. Levy
Howard A. Liebman
Tara L. Lin
Ton Lisman
Frederick L. Locke
Sagar Lonial
Tiffany L. Lucas
Marlise R. Luskin
Leo Luznik
Ryan C. Lynch
Stephen MacDonald
John P. Manis
Deepa Manwani
Camila Masias
Jennifer McNeer
Robert T. Means
Matthew G. Mei
Reid W. Merryman
Saskia Middeldorp
Tamara P. Miller
Alice S. Mims
Alison J. Moskowitz
Swati Naik
Eneida R. Nemecek
Cindy E. Neunert
Fionnuala B. Ní Áinle
Marena Rebekka Niewisch
Sven R. Olson
Timothy S. Olson
Giovanni Palladini
Jeanne M. Palmer
Anand A. Patel
Dipti Patel-Donnelly
Steven Z. Pavletic
Françoise Pirenne
Allyson Pishko
Kateřina Machová Poláková
Daniel A. Pollyea
Keith W. Pratz
Muna Qayed

Christian Récher
Jean-Antoine Ribeil
Lara N. Roberts
David A. Sallman
Bethany T. Samuelson
Bannow
Sharon A. Savage
Bipin N. Savani
Jordan K. Schaefer
Gary J. Schiller
Alvin H. Schmaier
Kirk R. Schultz
Roger E. G. Schutgens
Mikael A. Sekeres
Nirali N. Shah
Urvi A. Shah
Naranie
Shanmuganathan
Jeff P. Sharman
Joseph J. Shatzel
Akiko Shimamura
Michelle Sholzberg
Roni Shouval
Deborah M. Siegal
Leslie Skeith
Heather J. Symons
Zbigniew Macdonald
Szczepiorkowski
Jecko Thachil
Alexis A. Thompson
Andreas Tiede
Chaitra Ujjani
Rolf T. Urbanus
Celalettin Ustun
Jurjen Versluis
Adrianna Vlachos
Alison R. Walker
Alan S. Wayne
Jason R. Westin
Joshua F. Zeidner
Jeffrey A. Zonder

Continuing Medical Education Information

The *Hematology ASH Education Program* is an annual publication that provides practicing hematologists with invaluable information on the most important areas of clinical progress.

Hematology 2023 is a peer-reviewed collection of articles written by the 2023 ASH Education Program speakers and the Ham-Wasserman Lecturer. The papers showcase groundbreaking advances and new concepts in 31 different fields. Every year, the periodical provides an updated and comprehensive review of each of the topics covered in the annual meeting education sessions.

Educational objectives

1. Employ the knowledge gained regarding the diagnosis and treatment of malignant and classical hematologic disorders to improve patient care.
2. Discuss the state-of-the-art therapeutics in hematology.
3. Analyze the potential contribution of novel, not-yet-approved modalities of therapy to current evidence-based management of malignant and classical hematologic disorders.

Date of release

December 2023

Date of expiration

On December 31, 2024, the ability to earn Continuing Medical Education (CME) credit and American Board of Internal Medicine (ABIM) Maintenance of Certification (MOC) points for this product expires. This is the last date for users to claim credit for this product. For questions about credit, please contact the ASH Education Department at cme@hematology.org or call 866-828-1231 (toll-free) within the United States only or 1-202-776-0544 internationally.

Accreditation and credit designation

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ASH designates this enduring material for a maximum of 40 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians who participate in this CME activity but are not licensed in the United States are also eligible for *AMA PRA Category 1 Credit*[™]. To earn these credits, readers must pass two online tests (malignant and classical) based on articles from *Hematology 2023*.



ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 40 MOC points in the ABIM's MOC program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.



Claiming CME credits and ABIM points

The estimated time to complete this educational activity is 40 hours. To claim CME credit, users must complete an evaluation of the product and a test of medical knowledge, both of which are accessed through ASH Academy on Demand (academy.hematology.org). There is a one-time processing fee for claiming CME/MOC credit. Users with scores of 80% or better on these self-assessment modules are eligible to claim credit for the activity.

To facilitate claiming of credit, the test for this product is divided into two subtests, one of which focuses on malignant hematology content with the other focusing on classical content. Successful completion of each test earns the user 20 *AMA Category 1 PRA Credits*[™]. Users claim CME and/or ABIM MOC credit for each test individually. You can take one or both tests, depending on your CME and MOC needs.

The malignant and classical hematology tests consist of 20 questions each. The questions in each test can be answered in one sitting, or a user can save their progress and return to complete the test at a later time.

The malignant hematology test covers information presented in the following sections:

- Are We Personalizing MDS Therapy in 2023?
- CAR T Cells in ALL: Bridge or Definitive Therapy?
- Graft-Versus-Host Disease: Is an Ounce of Prevention Worth a Pound of Cure?
- Have We Optimized Therapy Yet for Patients with AML?
- How Can We Manage High-Risk Hematologic Malignancies in the Community?
- How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T Cells and Bispecific Antibodies
- How Do We Calibrate Cellular Therapy for Lymphoma In 2023?
- How Do We Enhance Results in Rare Hematologic Malignancies?
- How Do We Extend Survival for Patients with CLL In 2023?
- How Do We Improve Outcomes in Relapsed and Refractory Multiple Myeloma in 2023?

- How Do We Tackle Remaining Clinical Challenges in CML?
- How Is the Management Paradigm Evolving for Hodgkin Lymphoma in 2023?
- Not Kids Anymore and Not Adults Yet: How Do We Treat Adolescent and Young Adult (AYA) Patients with ALL?
- What Are the Advances in Myeloproliferative Neoplasms Affecting Management?
- What Are Treatment Options for Patients with Relapsed, Refractory, or Persistent AML?
- What Makes a Good Transplant Recipient? Putting the Puzzle Pieces Together
- Goldilocks and Transplant Timing in Inherited Marrow Failure Syndromes: Too Early, Too Late, Just Right?
- Ham-Wasserman Lecture
- Hematologic Toxicity of Immunotherapies
- Hematologists and the Care of Pregnant Women
- Hematologists as Lifesavers: Inpatient Hematology Emergencies
- Hemostasis in Patients with Severe Liver Disease
- Hot Topics in Blood Donation: Donor Risks and Social Justice
- Improving Outcomes for Individuals with Sickle Cell Disease: Are We Moving the Needle?
- Inherited Bone Marrow Failure Syndromes: from Pediatrics to Adult
- Ongoing Challenges in the Management of VTE
- The Iron Revolution!
- Transfusion Support in Sickle Cell Disease
- Why Am I Getting Paged at 2 AM? Microangiopathic Emergencies

The classical hematology test covers information presented in the following sections:

- Acquired Hemophilia A Diagnosis and Management
- Alphabet Soup: Challenging Consults on the Pediatric Units
- Energizing the Red Cell: Pyruvate Kinase Activators for Treatment of Hereditary Hemolytic Anemias